Development of a universal HIV-1 vaccine

开发通用 HIV-1 疫苗

• 批准号: G0701669/1
• 负责人: Tomas Hanke
• 金额: $ 165.71万
• 依托单位: University of Oxford
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2008
• 资助国家: 英国
• 起止时间: 2008 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=G0701669%2F1
• 关键词: Development; universal; HIV; vaccine

HIV infection and AIDS continues to spread in a virtually uncontrolled manner. The best and possibly only hope to change this alarming situation is a safe, effective, accessible protective vaccine. Arguably the biggest challenge in developing such a vaccine is the enormous HIV variability, which dwarfs almost any other infection. However, all parts of the virus cannot easily change. To remain alive, HIV has to keep some smaller regions of its proteins more or less constant. We have taken an advantage of this and constructed a simple candidate vaccine designed specifically to overcome the HIV variability by focusing the body defences on the conserved viral parts. Here, we are proposing to test this approach for the first time in a small pilot study in healthy individuals in Oxford. Successful outcome of this study would strongly support further evaluation of this vaccination strategy in larger and more expensive clinical studies.

艾滋病毒感染和艾滋病继续以几乎不受控制的方式传播。最好的，甚至可能只希望改变这种令人震惊的情况是一种安全，有效，易于使用的防护疫苗。可以说，开发这种疫苗的最大挑战是巨大的艾滋病毒变异性，它几乎使任何其他感染都相形见war。但是，病毒的所有部分都无法轻易改变。为了保持活力，艾滋病毒必须或多或少地保持其蛋白质的一些较小区域。我们已经利用了这一点，并构建了一种简单的候选疫苗，专门为克服艾滋病毒的变异性而设计，通过将身体防御重点放在保守的病毒部位上。在这里，我们建议在牛津健康个体的一项小型试点研究中首次测试这种方法。这项研究的成功结果将在更大，更昂贵的临床研究中强烈支持对这种疫苗接种策略的进一步评估。